At the time of writing, Palvella Therapeutics Inc [PVLA] stock is trading at $98.03, up 4.19%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PVLA shares have gain 20.08% over the last week, with a monthly amount glided 34.29%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Palvella Therapeutics Inc [NASDAQ: PVLA] stock has seen the most recent analyst activity on November 19, 2025, when Raymond James upgraded its rating to a Strong Buy but kept the price target unchanged to $143 for it. Previously, Oppenheimer started tracking the stock with Outperform rating on September 09, 2025, and set its price target to $85. On August 06, 2025, Raymond James initiated with an Outperform rating and assigned a price target of $54 on the stock. Truist started tracking the stock assigning a Buy rating and suggested a price target of $56 on July 21, 2025. Chardan Capital Markets initiated its recommendation with a Buy and recommended $50 as its price target on April 09, 2025. Stifel started tracking with a Buy rating for this stock on March 26, 2025, and assigned it a price target of $45. In a note dated March 07, 2025, Scotiabank initiated an Sector Outperform rating and provided a target price of $50 on this stock.
For the past year, the stock price of Palvella Therapeutics Inc fluctuated between $11.17 and $101.94. Currently, Wall Street analysts expect the stock to reach $119.71 within the next 12 months. Palvella Therapeutics Inc [NASDAQ: PVLA] shares were valued at $98.03 at the most recent close of the market. An investor can expect a potential return of 22.12% based on the average PVLA price forecast.
Analyzing the PVLA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is -0.73 and Total Capital is -0.39.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 94.18 points at the first support level, and at 90.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 103.40, and for the 2nd resistance point, it is at 108.76.
Ratios To Look Out For
It is important to note that Palvella Therapeutics Inc [NASDAQ:PVLA] has a current ratio of 6.49. As well, the Quick Ratio is 6.49, while the Cash Ratio is 6.16. Considering the valuation of this stock, the price to sales ratio is 859.51, the price to book ratio is 28.10.
Transactions by insiders
Recent insider trading involved Goin Kathleen, Chief Operating Officer, that happened on Nov 19 ’25 when 4302.0 shares were sold. Officer, Goin Kathleen completed a deal on Nov 19 ’25 to buy 4302.0 shares. Meanwhile, Director JENKINS GEORGE M bought 2490.0 shares on Apr 09 ’25.
